Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Idexx Laboratories



) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.9%. By the end of trading, Idexx Laboratories fell $3.35 (-3.7%) to $86.65 on heavy volume. Throughout the day, 3,165,938 shares of Idexx Laboratories exchanged hands as compared to its average daily volume of 370,800 shares. The stock ranged in price between $83.05-$88.21 after having opened the day at $83.84 as compared to the previous trading day's close of $90.00. Other companies within the Health Care sector that declined today were:

Biota Pharmaceuticals



), down 61.1%,




), down 13.5%,

Catalyst Pharmaceutical Partners



), down 13.2% and

ARCA biopharma



), down 11.0%.

  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

IDEXX Laboratories, Inc. develops, manufactures, and distributes various products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. Idexx Laboratories has a market cap of $4.9 billion and is part of the drugs industry. The company has a P/E ratio of 28.6, above the S&P 500 P/E ratio of 17.7. Shares are down 2.4% year to date as of the close of trading on Monday.

TheStreet Ratings rates Idexx Laboratories as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front,

Sucampo Pharmaceuticals Inc. A



), down 24.1%,

Celsion Corporation



), down 15.0%,

Oramed Pharmaceuticals



), down 13.6% and




), down 13.3% , were all gainers within the health care sector with

Baxter International



) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.